Background: Recurrent otitis media is a common problem in young children. Echinacea and osteopathic manipulative treatment have been proposed as preventive measures, but have been inadequately studied. This study was designed to assess the efficacy of Echinacea purpurea and/or osteopathic manipulative treatment (OMT) for prevention of acute otitis media in otitis-prone children.
Background
By age 3 years, most children (50-84%) experience at least one episode of acute otitis media (AOM). Recurrent otitis media is also common; 10% to 19% of children suffer 3 or more episodes during the first year alone [1] . In children with recurrent otitis media, conventional approaches to decreasing the risk of further episodes include prophylactic antibiotic therapy and surgical insertion of tympanostomy tubes to prevent accumulation of middle ear effusion. The effectiveness of these approaches is limited and controversial [2, 3] .
Complementary and alternative medicine (CAM) use in pediatric patients remains relatively common. One survey of parents at an urban pediatric emergency department reported an overall incidence of CAM use of 15%. Herbal remedies were used by 40% of those families that reported use of CAM modalities [4] . CAM approaches are often used for treatment of recurrent otitis media. A survey of pediatric clinic patients in Quebec revealed that ear, nose, and throat problems accounted for 24% of child visits to alternative medicine practitioners [5] , and a survey of parents at a British pediatric otolaryngology clinic found that 29% reported CAM use, with echinacea and manipulative treatments frequently cited [6] .
A recent report suggested a benefit of osteopathic manipulative treatment (OMT) in reducing episodes of AOM in otitis-prone children [7] . The osteopathic concept of recurrent otitis media postulates that predisposing structural dysfunction contributes to Eustachian tube dysfunction and is amenable to treatment with OMT, particularly in the cranial region [8] [9] [10] [11] .
Echinacea is an herb commonly used for treatment of upper respiratory tract infections. In vitro studies suggest a stimulatory effect of Echinacea purpurea preparations on various components of the immune system [12] [13] [14] . Several studies demonstrate improvement in the severity and duration of the common cold in adults treated with echinacea products [15] . Others, including the most rigorous study in children, show no benefit [16, 17] . Because most episodes of AOM follow upper respiratory tract infections, it is plausible that treatment of such infections with echinacea might decrease the risk of subsequent AOM.
We conducted a randomized, double-blind, placebo controlled trial between 1999 -2002 to assess the efficacy of echinacea treatment (at the time of upper respiratory infections) and OMT for the prevention of AOM in children with recurrent otitis media.
Methods

Definitions
No generally accepted diagnostic definition for AOM existed at the time of our study [18] . We defined AOM as an acute illness with at least one symptom (fever, rhinorrhea, cough, otalgia, irritability, lethargy, anorexia, vomiting, or diarrhea) and at least two otoscopic findings of middle-ear inflammation (injection, opacity, fullness, or impaired mobility) or purulent otorrhea. This definition is consistent with the later 2004 American Academy of Pediatrics guidelines on otitis media [19] . Recurrent otitis media was defined as at least 3 separate episodes of AOM within a 6-month period, or 4 episodes in one year. In order for episodes to be considered separate, the protocol required otoscopic documentation of resolution of one episode, or at least two weeks without symptoms following completion of antibiotic therapy, prior to onset of the subsequent episode.
Subjects
Children aged 12-60 months with recurrent otitis media (as documented in their medical records) were recruited from the Arizona Health Sciences Center Pediatric Clinic and from private pediatric offices in Tucson, Arizona. Children were excluded for unwillingness to participate, congenital malformations of the ears, nose, or throat (e.g., cleft palate), known or suspected allergy to echinacea, immune deficiency including HIV infection, or tuberculosis. Children taking prophylactic antibiotics or who had tympanostomy tubes in place were excluded from enrollment. The Arizona Health Sciences Center Pediatric Clinic serves an urban population, of which approximately 75% are covered by Medicaid.
Randomization
Randomization was done in blocks of eight using a random number table by a clinical pharmacist (KLG) having no contact with participants. Children were randomly assigned to one of four groups in a two-by-two factorial design. The first group received placebo extract orally and sham manipulation. The second group received Echinacea purpurea extract and sham manipulation. The third group received placebo extract and true OMT. The last group received Echinacea purpurea extract and true OMT. Sequentially numbered, indistinguishable bottles of echinacea or placebo were provided in advance. After informed consent was obtained, the parent was given the next bottle in sequence, and the pharmacist was telephoned to determine which of two osteopathic physicians was assigned (also determined randomly). The osteopathic physician independently contacted the pharmacist to learn whether a child was to receive sham or true osteopathic manipulative treatment. Children, families, and pediatricians were blinded to the group assignment of each subject.
Interventions
Children assigned to echinacea treatment received a 1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea manufactured by Eclectic Institute, Inc. (Sandy, Oregon). All echinacea came from the same lot number, with an analysis by the manufacturer confirming 50% root and seed extract of Echinacea purpurea. A similar, identically labeled placebo prepared by Eclectic Institute contained 50% ethanol, 45% filtered water, food coloring and thickeners. Parents were instructed to give 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
All children were scheduled for osteopathic sessions as soon as possible after entry, then 2, 4, 8, and 12 weeks later. At each visit, children assigned to OMT received diagnostic examinations and concurrent treatments as deemed necessary by the treating physician. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly). These treatments consist of gentle manipulations of the cranium, pelvis, diaphragm, and other structures. No high velocity or thrusting maneuvers were performed. At the discretion of the osteopathic physician, an osteopathic percussion hammer could also be used for treatment, which allowed gentle vibration in tissues at variable frequencies. Children assigned to sham manipulation received an osteopathic examination only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
The osteopathic physicians were well-respected members of the Tucson osteopathic community with practices restricted to manipulative treatment. All were members of the American Academy of Osteopathy and the Cranial Academy.
In addition to the study interventions, all parents received educational materials regarding otitis risk factors. If after enrollment a child received prophylactic antibiotics, otolaryngology referral, or tympanostomy tubes (usually for further recurrences of AOM), this information was recorded, but the child was allowed to remain in the study. Such decisions were made on clinical grounds by the treating clinician and were not influenced by the child's participation in the study.
Follow-up
After enrollment, children were prospectively followed for 6 months, with monthly telephone contact, and availability for evaluation 5 days per week by study pediatricians (MBA and RAW) if AOM was suspected. Children diagnosed with ear infection during weekends were asked to see one of the study physicians early the following week to confirm the diagnosis. In addition, children received otoscopic and physical examinations at entry, at 3 months, and at 6 months by study pediatricians, who were blinded to the treatment assignment of subjects.
Data collection
At enrollment, a questionnaire was used to collect information about the child's previous episodes of AOM, past medical history, cigarette smoke exposure, previous use of study alternative interventions, family history of allergy, and recurrent otitis media. The results of otoscopic and physical examinations were recorded at entry, 3, and 6 months, and at the time of any evaluation for possible AOM. At monthly telephone contacts, parents were asked if the child had any suspected or diagnosed ear problems during the previous month, and whether any side effects of the interventions were suspected. Parents were also asked at the 3-and 6-month visits whether they believed their child was receiving placebo for each study intervention.
Main outcome measures
The primary study outcome was the occurrence of a first episode of AOM during the study period as defined above. The final analysis was performed using only episodes of AOM that were sufficiently well documented in the medical record to meet the definition as described in the paper. A secondary outcome was the number of episodes of AOM. For this secondary outcome measure, all physician-diagnosed episodes of AOM were included, without respect to the case definition for AOM.
Analysis
Children were analyzed in the groups into which they were randomized. An initial analysis was done to determine if there was any important interaction between the effects of echinacea and OMT on the occurrence of AOM. Since none was found, the two interventions were considered independently. For each intervention, the cumulative incidence of AOM during follow-up was compared between treatment and placebo groups using chi-square analysis and the relative risk (RR) with 95% confidence interval (CI). P was considered significant at P < 0.05. The time to first episode of AOM was compared between groups using Kaplan-Meier analysis and the log rank test. Kaplan-Meier curves were truncated at 200 days of followup. Cox regression was used to estimate the relative risk of AOM during follow-up with adjustment for confounding effects of other factors. The median number of episodes of AOM during follow-up was compared using the MannWhitney nonparametric test. Analyses were performed using SPSS for Windows (Version 11.5.0, SPSS Inc., Chicago, IL) and EpiInfo (Version 5.01b, CDC and USD, Inc., Stone Mountain, GA).
Sample size
We assumed the risk of having at least one episode of AOM during 6 months of observation among children with recurrent otitis media to be 60%. With no effect modification between echinacea and osteopathic treatment, a final sample of 100 children (50 subjects per group for each analysis), was needed to provide 80% power to detect a 50% reduction in the risk of AOM associated with the treatment being analyzed (alpha = 0.05). This magnitude of risk reduction is comparable to that observed with antibiotic prophylaxis [20] .
The study was conducted with the approval of the University of Arizona Human Subjects Committee, and informed consent was obtained from a parent or guardian of each subject.
Results
Ninety children were enrolled in the study, 74 from the university-based clinic and 16 from private practice sites. Subjects had a median age of 1.5 years. The majority was male (57%) and white non-Hispanic (44%) or Hispanic (39%). Despite randomization, there were notable differences among treatment groups in the frequency of potentially confounding factors, especially gender, presence of siblings in the home, frequency of AOM prior to study entry, and daycare attendance (Table 1) .
Six subjects (7%) withdrew or were lost to follow-up within 3 months of enrollment (1-2 in each group). Only 19% of subjects attended all 5 scheduled osteopathic visits, but 64% had 3 or more treatment visits (see CON-SORT diagram [21] : Additional file 1). The percentage of subjects that came for follow-up examinations was 69% at 3 months and 62% at 6 months. Medical record information on the occurrence of AOM during at least 3 months of follow-up was available for 84 subjects (93%). The length of follow-up ranged from 2 to 278 days (median 183).
Of 84 children followed for 3 months or more, 44 (52%) had one or more episodes of AOM as defined above. The cumulative incidence of AOM varied from 39% to 80% among the treatment groups (P = 0.04) (Figure 1) . The highest rate of AOM was among children receiving echinacea alone.
The pattern of variation in incidence rates among the treatment groups did not suggest any plausible effect modification between echinacea treatment and OMT on the risk of AOM (Figure 1 ). In addition, a likelihood ratio test for interaction between the two treatments using Cox regression was not significant (P = 0.40). Therefore, the independent effects of echinacea and OMT were assessed separately.
The use of echinacea was associated with an increased risk of AOM of borderline statistical significance. Sixty-five percent of children assigned to echinacea experienced AOM compared to 41% of children taking placebo (RR 1.59, 95% CI 1.04, 2.42). The Kaplan-Meier analysis using all 90 subjects yielded nearly identical results (Figure 2 ).
OMT was not significantly associated with the risk of AOM. Forty-four percent of children receiving OMT experienced AOM compared to 61% of children undergoing (Figure 3) .
We estimated the effects of echinacea and OMT on the risk of AOM after adjustment for confounding factors using Cox regression in all 90 subjects ( Table 2 ). The adjusted relative risk of AOM for echinacea treatment was 1.73 (95% CI 0.94, 3.18). The adjusted relative risk for OMT was 0.84 (95% CI 0.44, 1.61). Four variables (younger age, male gender, Hispanic ethnicity, and presence of one or more siblings at home) were independently associated with the risk of AOM and were included in the regression model.
There was no significant difference in the median number of episodes of AOM during the study period between treatment and placebo groups for either echinacea or OMT. Comparisons were made using the Mann-Whitney nonparametric test.
One subject withdrew from the study following an adverse effect (vomiting after taking the echinacea placebo). One additional subject reported adverse effects (vomiting and non-urticarial rash two days after starting echinacea for a viral upper respiratory illness) but did not withdraw. Neither adverse effect was considered to have been caused by the study medication. As reported in monthly telephone interviews and at the 3-and 6-month visits, there was no statistically significant difference in reporting of any side effects between placebo and treatment groups for either echinacea or OMT.
Parents were unable to distinguish whether their child was receiving echinacea treatment or placebo. However, when asked about OMT after 3 months, parents of children assigned to OMT were significantly more likely to believe their child was receiving actual OMT than parents of children assigned to sham (Figure 4 ). Even so, only 20% of parents of children assigned to sham treatments believed their child to be receiving placebo. Interestingly, the ability to distinguish OMT from sham treatment disappeared entirely by 6 months.
Cumulative incidence of AOM according to assigned treatment group Figure 1 Cumulative incidence of AOM according to assigned treatment group. The P value is for at least one group being significantly different from the others.
Discussion
We found that preventive treatment with osteopathic manipulation did not result in a statistically significant decrease in the risk of AOM in otitis-prone children. Treatment with an alcohol extract of Echinacea purpurea root and seeds at times of upper respiratory infection was associated with a modestly increased risk of AOM. This effect was of borderline statistical significance and may have been due to chance.
As noted, the randomization process resulted in an unequal distribution of certain otitis risk factors among treatment groups. The group receiving echinacea alone appeared to be at higher risk based on several factors, and this chance occurrence may have been responsible for the higher rate of otitis in the echinacea group. We adjusted for known confounding factors, resulting in modest changes in relative risk estimates, but the possibility of incomplete adjustment, or unmeasured confounding by other factors cannot be excluded. This is the first randomized, placebo-controlled trial of Echinacea purpurea for the prevention of AOM. We chose to treat children at the time of upper respiratory tract infections, rather than using a prolonged preventive regimen, based on the finding that echinacea appeared to be more effective in treatment than prevention of URI in adults [22] . Two subsequent randomized trials did not confirm this pattern in children. Taylor and colleagues found the pressed juice of E. purpurea aerial plant to be of no benefit to children in treatment of the common cold [16] . Cohen reported a significant reduction in colds and other respiratory outcomes following preventive use of a product containing liquid extracts of E. purpurea aerial plant, E. angustifolia root, propolis, and vitamin C [23] . The latter study also showed a decreased risk of acute otitis media with the echinacea product, but was not designed to measure this outcome in a rigorous way. Recent studies have confirmed our premise that AOM in children is a frequent complication of viral upper respiratory tract infection [24, 25] .
Kaplan-Meier estimates of the probability of AOM according to treatment with echinacea or placebo Echinacea  44  30  21  16  4  Placebo  46  35  30  28  8 Research on the therapeutic use of echinacea is complicated by the fact that there are three species of echinacea in common use, and preparations are made from various combinations of leaves, flowers, roots, and seeds of the plant. Furthermore, various methods of preparation are used, including alcohol or glycerin extraction, desiccation, and juicing. These issues are discussed elsewhere with respect to the present study [26] . Our results cannot be generalized to other forms of echinacea.
No. at Risk
One previous study evaluated OMT for prevention of AOM in otitis-prone children [7] . The authors reported a statistically significant decreased frequency of AOM episodes and fewer surgical episodes among treated children. That protocol called for 9 osteopathic treatment visits, compared with 5 in the present study. As noted by the authors, that study did not have a placebo control, and the control group had a very high dropout rate, a combina- tion of factors with a significant potential to introduce bias.
The main limitations of this study were small sample size and incomplete compliance with osteopathic treatments and follow-up visits. Our final analysis involved 84 subjects, yielding 73% power to detect a 50% risk reduction under our initial assumptions. The borderline increased risk associated with echinacea treatment make a protective effect of this form and dosage schedule of echinacea very unlikely, despite the sample size.
Because we were able to identify episodes of AOM through medical record review, the incomplete compliance with follow-up pediatrician visits had limited impact on our findings. However, it is possible that the lack of a statistically significant benefit found for OMT was the result of inadequate compliance with OMT visits. An analysis restricted to subjects attending 3 or more treatment visits did not suggest a greater protective effect of OMT, but the sample size was small. On the other hand, research personnel exerted considerable effort at getting subjects to these visits, with limited success, perhaps because the children were not ill at those times. An analysis of the reasons for limited participation by families with OMT may be useful for future OMT research.
An ancillary purpose of this study was to determine if a suitable sham for osteopathic manipulation could be devised. A previous study of sham chiropractic treatment in children did not evaluate how parents perceived the sham treatment [27] . We hoped to be able to show that parents would be unable to distinguish examination alone from examination and concurrent treatment. In fact, about 20% of parents of sham recipients (versus 4% in the true treatment group) correctly thought that the child was receiving sham manipulation. However, the large majority of parents of sham recipients could not tell that the "sham manipulation" was placebo. Some osteopathic physicians believe any "hands-on" contact has potential therapeutic benefit. To the extent this is true, our "sham" treatment could mask an actual benefit of OMT.
Conclusion
Treatment of upper respiratory infections in otitis-prone children with an alcohol extract of the roots and seeds of Echinacea purpurea does not decrease the risk of AOM, and may in fact increase risk. In the same population of children, a preventive regimen of from one to five osteopathic manipulative treatments over three months did not significantly decrease their risk of acute otitis media.
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